KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Holdings Raised by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 3.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 830,984 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,713 shares during the quarter. Geode Capital Management LLC owned approximately 1.92% of KalVista Pharmaceuticals worth $9,624,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Suvretta Capital Management LLC boosted its holdings in shares of KalVista Pharmaceuticals by 0.5% in the third quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock worth $48,775,000 after buying an additional 20,000 shares during the period. Vestal Point Capital LP lifted its position in shares of KalVista Pharmaceuticals by 73.9% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after acquiring an additional 1,700,000 shares in the last quarter. Great Point Partners LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at approximately $15,768,000. State Street Corp boosted its stake in KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after purchasing an additional 515,179 shares during the period. Finally, Emerald Advisers LLC grew its position in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares in the last quarter.

KalVista Pharmaceuticals Trading Up 1.0 %

Shares of NASDAQ:KALV opened at $8.47 on Thursday. The firm has a market cap of $418.57 million, a price-to-earnings ratio of -2.33 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.97 and a 1 year high of $16.88. The business has a fifty day simple moving average of $9.81 and a 200 day simple moving average of $11.44.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KALV shares. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Bank of America began coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th.

Insiders Place Their Bets

In other news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction on Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares of the company’s stock, valued at approximately $2,677,311. The trade was a 2.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,291 shares of company stock valued at $304,086 in the last three months. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).